Harding Thomas C.'s Form 4 filing
Clovis Oncology, Inc. (CLVS) · filed Mar 3, 2022
- Accession no.
- 0000899243-22-009060
- Filed
- Mar 3, 2022
- Trade date
- Mar 1-2, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 8 non-derivative transactions and 6 derivative transactions. Open-market sales total $14.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harding Thomas C.CIK 0001834833 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2022 | Common Stock | MOption exerciseAcquired | +282 | –F1 | – | 7,016 | Direct | |
| Mar 2, 2022 | Common Stock | SSaleDisposed | −166 | $1.87F3 | −$310.42 | 6,850 | Direct | |
| Mar 1, 2022 | Common Stock | MOption exerciseAcquired | +11,584 | –F1 | – | 18,434 | Direct | |
| Mar 2, 2022 | Common Stock | SSaleDisposed | −6,780 | $1.87F3 | −$12,678.6 | 11,654 | Direct | |
| Mar 1, 2022 | Common Stock | MOption exerciseAcquired | +19 | –F1 | – | 1,671 | Indirect | |
| Mar 2, 2022 | Common Stock | SSaleDisposed | −9 | $1.87F4 | −$16.83 | 1,662 | Indirect | |
| Mar 1, 2022 | Common Stock | MOption exerciseAcquired | +2,031 | –F1 | – | 3,693 | Indirect | |
| Mar 2, 2022 | Common Stock | SSaleDisposed | −871 | $1.87F4 | −$1,628.77 | 2,822 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2022 | Common Stock | AGrant or awardAcquired | +81,000 | $0.00 | $0 | 81,000 | Direct | |
| Mar 1, 2022 | Common Stock | AGrant or awardAcquired | +6,380 | $0.00 | $0 | 6,380 | Indirect | |
| Mar 1, 2022 | Common Stock | MOption exerciseAcquired | +11,584 | $0.00 | $0 | 34,750 | Direct | |
| Mar 1, 2022 | Common Stock | MOption exerciseAcquired | +282 | $0.00 | $0 | 0 | Direct | |
| Mar 1, 2022 | Common Stock | MOption exerciseAcquired | +19 | $0.00 | $0 | 0 | Indirect | |
| Mar 1, 2022 | Common Stock | MOption exerciseAcquired | +2,031 | $0.00 | $0 | 4,062 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Referenced by the price of 4 transactions in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $1.860 to $1.866. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 2 transactions in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $1.861 to $1.866. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 2 transactions in Table I.
Remarks
Executive Vice President and Chief Scientific Officer